0.05Open0.09Pre Close40 Volume664 Open Interest6.00Strike Price200.00Turnover175.53%IV11.06%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.1356Delta0.3130Gamma133.80Leverage Ratio-0.0486Theta0.0000Rho-18.15Eff Leverage0.0009Vega
Altimmune Stock Discussion
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune(ALT.US)$
No comment yet